Everest Medicines gets China NMPA approval for CARDAMYST® in PSVT
Everest Medicines announced China’s NMPA approval of CARDAMYST® for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.